{"nctId":"NCT01246973","briefTitle":"Oral Curcumin for Radiation Dermatitis","startDateStruct":{"date":"2011-02"},"conditions":["Radiation-induced Dermatitis"],"count":686,"armGroups":[{"label":"curcumin","type":"EXPERIMENTAL","interventionNames":["Drug: Curcumin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Curcumin","otherNames":["Curcumin C3 Complex"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* a diagnosis of non-inflammatory breast adenocarcinoma (including in situ and bilateral)\n* scheduled to begin radiotherapy without concurrent chemotherapy; concurrent hormone or Herceptin® (trastuzumab)treatment is okay\n* can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment\n* can have had breast reconstruction\n* scheduled to receive 25-35 radiation treatment sessions (1 session per day) using standard irradiation fractionation (1.8-2.0 Gy per sessions) OR 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session)(100, 101).\n* able to swallow medication.\n* three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study\n* able to understand English\n\nExclusion Criteria:\n\n* inflammatory breast cancer\n* previous radiation therapy to the breast or chest\n* concurrent chemotherapy treatment\n* concurrent treatment with anti-coagulants (e.g., coumadin®, warfarin®), or anti-EGFR (human epidermal growth factor receptor) drugs (e.g. Iressa® (gefitinib), Erbitux® (cetuximab, C225); aspirin is allowed\n* known radiosensitivity syndromes (e.g., Ataxia-telangiectasia)\n* collagen vascular disease, unhealed surgical sites, or breast infections","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"21 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Radiation Dermatitis Severity Score","description":"The outcome measures will be the severity of radiation dermatitis, using the Radiation Dermatitis Score (RDS), at the end of treatment in each treatment arm. (Objective: To examine the efficacy of curcumin in preventing and/or reducing the severity of dermatitis in radiation treatment site in breast cancer patients). The RDS score ranges from 0-4 with higher scores indicating worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"0.05"},{"groupId":"OG001","value":"1.99","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Moist Desquamation","description":"Moist desquamation was measured by the presence of wet, patchy crusting, oozing, or ulcerated skin in areas where skin was peeling in sheets.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.541","spread":null},{"groupId":"OG001","value":"12.203","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":344},"commonTop":[]}}}